Carl Spana's Contact Details

Carl Spana's Company Details

Palatin Technologies

Cranbury, NJ, US • 100 - 249 Employees
Major Drugs

Palatin (NYSE American: PTN) is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system. The melanocortin system is involved in regulating important physiological activities such as food intake and energy balance, desire and arousal, and the resolution of harmful inflammation. We are the first company to obtain FDA approval for a melanocortin based therapeutic, Vyleesi®, a treatment for women with hypoactive sexual desire disorder (HSDD).With the successful development of Vyleesi® and our extensive experience in the development of melanocortin based therapeutics, we are now focused on developing therapeutics that take advantage of the key role that the melanocortin system plays in the resolution of harmful inflammation. This has the potential to treat diseases that affect the eye, gastrointestinal system and the kidney. Our most advanced ocular product is PL9643, a topical treatment for dry eye disease, which is targeted to enter Phase 3 clinical trials in 2H 2021. We also have therapeutics in earlier stages of development for ophthalmic indications such as non-infectious uveitis, retinopathies and corneal diseases.Therapeutics that modulate the activity of the melanocortin system will have broad utility and to establish this, we are planning to conduct proof of concept clinical studies in ulcerative colitis and kidney disease. Vyleesi® is the first and only on-demand, FDA-approved treatment for premenopausal women suffering with HSDD, which affects 1 in 10 pre-menopausal women. Learn about this condition here: https://www.unblush.com/ To learn more about Vyleesi®, including Important Safety Information, visit here: https://www.vyleesi.com/ We are very excited by the tremendous potential our therapeutics have to positively impact the lives of patients and the value we can build for our shareholders. Find more information about our programs: www.palatin.com